BalchemBCPC +0.66%94 Debt-to-EBITDA is 0.69 as of Mar. 2026, which is 47% below its 10-year median of 1.30. GuruFocus rates BCPC with a GF Score™ of 94/100 and a GF Value™ of $177.50 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,229 Chemicals companies, Balchem ranks better than 73.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Balchem's Debt-to-EBITDA or its related term are showing as below:
BCPC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.67 Med: 1.3 Max: 2.35
Current: 0.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Balchem was 2.35. The lowest was 0.67. And the median was 1.30.
BCPC's Debt-to-EBITDA is ranked better than 73.39% of 1229
companies
in the Chemicals industry
Industry Median: 2.16
vs BCPC: 0.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Balchem Debt-to-EBITDA Related Terms
Balchem Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Balchem's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Balchem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balchem Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Balchem's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Balchem's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Balchem (BCPC) has a Debt-to-EBITDA of 0.69 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Balchem. This is 47% below median its historical median of 1.30. Over the past decade, Balchem's Debt-to-EBITDA has ranged from 0.67 to 2.35. According to the industry distribution chart, Balchem ranks #327 out of 1229 companies in the Chemicals industry, placing it in the top 26.6%.
Is Balchem's Debt-to-EBITDA too high?
Balchem's current Debt-to-EBITDA of 0.69 is 47% below median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 2.35. The Chemicals industry median Debt-to-EBITDA is 2.16. Balchem's value of 0.69 is 68.1% below this industry median. Based on the distribution chart, Balchem ranks #327 out of 1229 companies in the Chemicals industry, which is above the industry midpoint. Overall, Balchem has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Balchem's Debt-to-EBITDA compare to PRM and SXT?
According to the Chemicals industry distribution chart, Balchem ranks #327 out of 1229 companies for Debt-to-EBITDA. This puts Balchem in the upper half of its industry. The industry median Debt-to-EBITDA is 2.16. Balchem's value of 0.69 is 68.1% below this benchmark. Historically, Balchem's own Debt-to-EBITDA has ranged from 0.67 to 2.35 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 2.16, Balchem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.16, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balchem's current Debt-to-EBITDA of 0.69 is 68.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Balchem. For the Chemicals industry, the median Debt-to-EBITDA is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balchem's current Debt-to-EBITDA is 0.69, which is 47% below median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balchem stock overvalued right now?
Based on GuruFocus' analysis, Balchem (BCPC) is currently considered Fairly Valued. The stock's GF Value™ is $177.50, compared to a current price of $167.98 — trading 5.4% below its estimated fair value. The current Debt-to-EBITDA is 0.69, which is 47% below median its 10-year median of 1.30 and 68.1% below the Chemicals industry median of 2.16. Balchem's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Balchem (BCPC), the current Debt-to-EBITDA is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balchem (BCPC) Overvalued in 2026?
Based on GuruFocus' analysis, Balchem stock appears to be undervalued.
The current stock price of $167.98 is trading 5.4% below its estimated GF Value™ of $177.50.
GuruFocus considers Balchem to be Fairly Valued.
Key valuation signals for BCPC:
Debt-to-EBITDA: 0.69 (47% below median its 10-year median of 1.30)
GF Value™: $177.50 vs. price of $167.98 (5.4% below fair value)
Industry Position: 68.1% below the Chemicals median (#327 of 1229)
No single metric tells the full story. See the BCPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
94GF Score
Get the complete analysis for BCPC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCPC has been successfully added to your 
